Sign in to view content

ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD

Raj K. Maturi, MD

Video
Published 2023

Related

Wet AMD 3 Symposium
Annual Meeting Talks
2020
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Episode 9: Rate of Macular Atrophy in HARBOR Study with Dr. SriniVas Sadda
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more